Conba subsidiary gets drug approval after 627m yuan investment

Hangzhou Conba Pharmaceutical, a wholly-owned subsidiary of Zhejiang Conba Pharmaceutical, received drug registration approval for its 0.25g tranexamic acid tablets from the National Medical Products Administration.

The company invested approximately 627 million yuan in research and development for the generic drug, which treats various bleeding conditions. The domestic market for tranexamic acid tablets reached 263 million yuan in 2024, showing 12.24% year-on-year growth.